Human tissue and data for translational oncology
Connect quality biospecimens with clinical context, whole-slide images and biomarker characterization. Build research cohorts around the biology and treatment questions that matter to your study.
THE REPOSITORY
TriStar’s Oncology Translational Pathology Repository
Human biological samples and donor records form the foundation. Access matched images and add the assays needed to answer your research question.
Tissue linked to the donor record
Clinical context retained across samples, images and assay results.
HBS & DONOR DATA
Quality biospecimens & data for precision medicine
UK · Italy · FranceDonors from participating medical centers, with informed consent and ethics approval.
FFPE surgical samplesPrimary tumors, metastases and normal (non-malignant) tissue.
Breadth of donor profiles
Specimen, treatment, outcomes and molecular data, structured at the patient level.
Patient trajectory
- Primary tumors & matched distant metastases
- Matched normal tissue
- Neoadjuvant & adjuvant treatment
- Standard-of-care targeted therapies & checkpoint inhibitors
- Treatment regimen, line & dates
- Responders & non-responders
Structured outcomes
- Clinician-recorded response
- Overall survival (months)
- Progression-free survival (months)
- Time to events (months)
- Last follow-up
- Event flags: recurrence / death / composite
Molecular characterization
- IHC
- FISH
- RNA-ISH
- NGS: SNVs, CNVs & fusions
Records are fully anonymized. Available fields vary by donor and reflect clinical practice at the source center. Cohorts are selected to meet your project’s requirements.
TREATMENT & FOLLOW-UP
Treatment history represented in our donor records
Follow-up records include standard-of-care, targeted and immuno-oncology treatments. Explore examples of agents recorded across the dataset.
Immune checkpoint inhibitors & IO
- Atezolizumab
- Avelumab
- Dostarlimab
- Durvalumab
- Ipilimumab
- Nivolumab
- Pembrolizumab
- Tebentafusp
Monoclonal antibodies & ADCs
- Bevacizumab
- Cetuximab
- Panitumumab
- Trastuzumab
- Pertuzumab
- Sacituzumab govitecan
- Denosumab
- Infliximab
EGFR, ALK, MET, RET & KRAS inhibitors
- Afatinib
- Dacomitinib
- Erlotinib
- Gefitinib
- Osimertinib
- Alectinib
- Lorlatinib
- Tepotinib
- Selpercatinib
- Sotorasib
VEGF & multi-kinase inhibitors
- Axitinib
- Lenvatinib
- Nintedanib
- Pazopanib
- Regorafenib
- Sorafenib
- Sunitinib
- Tivozanib
BRAF, HER2 & other kinase inhibitors
- Dabrafenib
- Encorafenib
- Vemurafenib
- Lapatinib
- Neratinib
- Dasatinib
- Imatinib
- Saracatinib
CDK4/6, PI3K/mTOR & PARP inhibitors
- Abemaciclib
- Palbociclib
- Alpelisib
- Everolimus
- Niraparib
- Olaparib
- Rucaparib
Regimen, treatment line, dates, response and follow-up coverage vary by donor. These examples do not imply that every agent has an available matched tissue and image cohort.
IMAGE REPO & SCANNING
Whole-slide images linked to tissue and clinical data
Study tissue morphology alongside treatment, response and outcomes. Each image is linked to its matched surgical section, archived FFPE block and anonymized donor record.
Scanned in house on Aperio GT450 and AT2 scanners at 40×, with .svs files and review of slides and images by medical pathologists.
Explore Image & Clinical Data
Assays & pathology support
Integrated tissue assay services
Pair selected FFPE tissue and TMAs with assays and pathology guidance, planned around your study.
Protein expression
IHC assay services
Add protein-expression measurements with 100+ optimized IHC assays, or discuss assay development for a new target.
Explore IHC servicesSpatial RNA expression
RNAscope RNA-ISH
Localize target RNA in FFPE tissue, with pre-qualified samples, assay controls and pathologist scoring.
Explore RNAscopeMultiplex protein imaging
Multiplex immunofluorescence
Study protein co-expression, cell phenotypes and spatial relationships in selected FFPE tissue and TMAs.
100+ optimized IHC assays
Selected targets from the IHC library. Multiplex panels are reviewed separately.
Browse the IHC target library →IHC staining on Ventana and Dako platforms. Review and scoring by medical pathologists with pharmaceutical industry experience.
Work with our experienced scientific team to tailor biospecimens, data, and integrated services to your research needs.
Our approach begins with our customers’ science.
We focus our acquisition on patient cohorts that meet the needs of biopharma, clinical, and translational researchers.
PLAN YOUR COHORT
Define the tissue and data your study needs
Share your tumor type, cohort size and required clinical or molecular information. We will review available cases, images and any additional testing.